Like other developers of recently approved gene therapies, Bluebird has been slow to generate demand for its products. That reflects challenges in securing reimbursement from payers stemming from ...
In recent financial reports submitted to the Securities and Exchange Committee (SEC) in an 8-K filing, bluebird bio, Inc. (NASDAQ: BLUE), a leading biotech company, has provided an update on their ...
bluebird bio has its first ever product approval, getting a green light from the EMA for Zynteglo, its ex vivo gene therapy for the rare blood disorder beta thalassaemia. The EU regulator has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback